

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.535APPLICATION NO.
09/088,951

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

June 2, 1998

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
su	AA	4,205,130	05/27/80	Vihko	435	196	—
↓	AB	4,267,272	05/12/81	Josephson	435	7	—
	AC	4,510,239	04/09/85	Miller et al.	435	7	—
	AD	5,719,030	02/17/98	Kuroiwa et al.	435	7.1	—
	AE	5,738,867	04/14/98	Spitler	424	450	—
	AF	5,925,362	07/20/99	Spitler et al.	424	277.1	—
↓	AG	5,976,546	11/02/99	Laus et al.	424	192.1	—

FOREIGN PATENT DOCUMENTS

In		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
↓	AH	CA 1 185 525	04/16/85	Canada	✓	✓
	AI	WO 95/04548	02/16/95	PCT	✓	✓
	AJ	WO 98/46769	10/22/98	PCT	✓	✓

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	su	AK	Bakker et al., "Melanocyte Lineage-specific Antigen gp100 Is Recognized by Melanoma-derived Tumor-infiltrating Lymphocytes," <i>The Journal of Experimental Medicine</i> 179:1005-1009, 1994.
		AL	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185-HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer," <i>Journal of Clinical Oncology</i> 14(3):737-744, 1996.
		AM	Ben-Mahrez et al., "Circulating Antibodies Against C-MYC Oncogene Products In Sera Of Colorectal Cancer Patients," <i>Int. J. Cancer</i> 46:35-38, 1990.
		AN	Berchuck et al., "Overexpression of HER-2/neu Is Associated with Poor Survival in Advanced Epithelial Ovarian Cancer," <i>Cancer Research</i> 50:4087-4091, 1990.
		AO	Bernards et al., "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector," <i>Proc. Natl. Acad. Sci. USA</i> 84:6854-6858, 1987.
		AP	Cheever et al., "Specific Adoptive Therapy Of Established Leukemia With Syngeneic Lymphocytes Sequentially Immunized <i>In Vivo</i> And <i>In Vitro</i> And Nonspecifically Expanded By Culture With Interleukin 2," <i>The Journal Of Immunology</i> 126(4):1318-1322, 1981.

EXAMINER



DATE CONSIDERED

3/1 5/28/05

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.535APPLICATION NO.
09/088,951

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

June 2, 1998

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
			YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KA	Su	AA	Disis and Cheever, "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," <i>Advances in Cancer Research</i> 71:343-371, 1997.
		AB	Disis et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer," <i>Cancer Research</i> 54:16-20, 1994.
		AC	Disis et al., "Immunity to the HER-2/neu oncogenic protein," in <i>Vaccines Against Virally Induced Cancers</i> , John Wiley & Sons, Chichester, 1994, CIBA Foundation Symposium 187, pp. 198-211.
		AD	Disis et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2/neu, an Oncogenic Self Protein," <i>The Journal of Immunology</i> 156:3151-3158, 1996.
		AE	Disis et al., "Immunization with Homologous Foreign Proteins Generates Immunity Against "Self" Tumor Antigens," <i>The FASEB Journal Abstracts</i> 10(6):p. A1470, Abstract No. 2709, 1996.
		AF	Fisk et al., "Identification of an Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines," <i>J. Exp. Med.</i> 181:2109-2117, 1995.
		AG	Gaugler et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Bytolytic T Lymphocytes," <i>J. Exp. Med.</i> 179:921-930, 1994.
		AH	Gusterson et al., "Prognostic Importance of c-erbB-2 Expression in Breast Cancer," <i>Journal of Clinical Oncology</i> 10(7):1049-1056, 1992.
		AI	Houghton, "Cancer Antigens: Immune Recognition of Self and Altered Self," <i>J. Exp. Med.</i> 180:1-4, 1994.
		AJ	Katsumata et al., "Prevention of breast tumor development <i>in vivo</i> by downregulation of the p185 ^{neu} receptor," <i>Nature Medicine</i> 1(7):644-648, 1995.
		AK	Kawakami et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes," <i>The Journal of Experimental Medicine</i> 180:347-352, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.535APPLICATION NO.
09/088,951

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

June 2, 1998

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	SM	AA	Kern et al., "p185 ^{neu} Expression in Human Lung Adenocarcinomas Predicts Shortened Survival," <i>Cancer Research</i> 50:5184-5191, 1990.
		AB	Mahi-Brown et al., "The cellular immune response to immunization with zona pellucida antigens," <i>Journal of Reproductive Immunology</i> 21:29-46, 1992.
		AC	Mamula et al., "Breaking T Cell Tolerance With Foreign And Self CO-Immunogens. A Study of Autoimmune B and T Cell Epitopes of Cytochrome c," <i>The Journal of Immunology</i> 149(3):789-195, 1992.
		AD	Mamula, "The Inability to Process a Self-Peptide Allows Autoreactive T Cells to Escape Tolerance," <i>J. Exp. Med.</i> 177:567-571, 1993.
		AE	Matyas et al., "OncoVax PTM vaccine for prostate cancer induces immune responses to prostate specific antigen in prostate cancer patients," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 40: 576-577, 1999.
		AF	Naftzger et al., "Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity," <i>Proc. Natl. Acad. Sci. USA</i> 93:14809-14814, 1996.
		AG	Nanda and Sercarz, "Induction of Anti-Self-Immunity to Cure Cancer," <i>Cell</i> 82:13-17, 1995.
		AH	Peoples et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide," <i>Proc. Natl. Acad. Sci. USA</i> 92:432-436, 1995.
		AI	Schlichtholz et al., "The Immune Response to p53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot," <i>Cancer Research</i> 52:6380-6384, 1992.
		AJ	Skinner et al., "Characterization of antigenicity and immunogenicity pattern of native and recombinant zona pellucida proteins in the white-tailed deer (<i>Odocoileus virginianus</i>)," <i>Journal of Reproduction and Fertility</i> 101:295-303, 1994.
		AK	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," <i>Science</i> 235: 177-182, 1987.
		AL	Takahashi et al., "Antibody to ras Proteins in Patients with Colon Cancer," <i>Clinical Cancer Research</i> 1:1071-1077, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.535APPLICATION NO.
09/088,951

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

June 2, 1998

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	SM	AA	Talmadge et al., "Preclinical evaluation of OncoVax-P a prostate cancer vaccine," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 37: p. 477, 1996.
KAC	SM	AB	Yonemura et al., "Evaluation of Immunoreactivity for erB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer," <i>Cancer Research</i> 51:1034-1038, 1991.
		AC	
		AD	
		AE	
		AF	
		AG	
		AH	
		AI	
		AJ	
		AK	
		AL	

EXAMINER

DATE CONSIDERED

A. S. [Signature]

3/1/00

5/25/05

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).